| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-�eB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells
|
Wu C.-H.; Yang Y.-H.; Chen M.-R.; Tsai C.-H.; ANN-LII CHENG; Doong S.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
The APPLE Association President's Message
|
ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
|
Chang C.-J.; Yang Y.-H.; Chiu C.-J.; Lu L.-C.; Liao C.-C.; Liang C.-W.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Adiposity, inflammation, and breast cancer pathogenesis in Asian Women
|
Iyengar N.M.; Chen I.-C.; Zhou X.K.; Giri D.D.; Falcone D.J.; Winston L.A.; Wang H.; Williams S.; Lu Y.-S.; Hsueh T.-H.; ANN-LII CHENG; Hudis C.A.; Lin C.-H.; Dannenberg A.J. |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
|
Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
|
Bouattour M.; Raymond E.; Qin S.; ANN-LII CHENG; Stammberger U.; Locatelli G.; Faivre S. |
| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Reply to: ��Predictors of sorafenib benefit in patients with hepatocellular carcinoma��
|
Bruix J.; ANN-LII CHENG; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice
|
Tsai C.-L.; Liu W.-L.; Hsu F.-M.; Yang P.-S.; Yen R.-F.; Tzen K.-Y.; ANN-LII CHENG; Chen P.-J.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
The HER2 inhibitor lapatinib potentiates doxorubicininduced cardiotoxicity through iNOS signaling
|
Hsu W.-T.; Huang C.-Y.; Yen C.Y.T.; ANN-LII CHENG; Hsieh P.C.H. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
|
Bruix J.; ANN-LII CHENG; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
|
Chen I.-C.; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
|
Shao Y.-Y.; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients
|
Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy
|
Yang S.-H.; Lee J.-C.; Guo J.-C.; Kuo S.-H.; Tien Y.-W.; Kuo T.-C.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Asia�VPacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|
Omata M.; ANN-LII CHENG; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; Chen P.-J.; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. |
